NEVVI Medicare utilization intelligence

← back

DAR, AJAYM.D. NPI 1215905286 Clinician

Medical Oncology · LEESBURG, VA

Specialty Medical Oncology — from billed Medicare claims
In practice about 42 years since medical school (class of 1984, self-reported to CMS)
Location LEESBURG, VA · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 74 codes billed · 54,013 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
VIRGINIA CANCER SPECIALISTS, P.C.
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2025-11

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9271 Injection, pembrolizumab, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
J0640 Injection, leucovorin calcium, per 50 mg
88185 Flow cytometry technique for dna or cell analysis, each additional marker
J9190 Injection, fluorouracil, 500 mg
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
82784 Gammaglobulin (immune system protein) measurement
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J1626 Injection, granisetron hydrochloride, 100 mcg
J2469 Injection, palonosetron hcl, 25 mcg
83883 Nephelometry, test method using light
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J9045 Injection, carboplatin, 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J3489 Injection, zoledronic acid, 1 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
84165 Protein measurement, serum
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
84153 Psa (prostate specific antigen) measurement, total
86334 Immunologic analysis technique on serum (immunofixation)
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96372 Injection of drug or substance under skin or into muscle
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
83615 Lactate dehydrogenase (enzyme) level
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
81002 Urinalysis, manual test
85046 Red blood count automated, with additional calculations
82378 Carcinoembryonic antigen (cea) protein level
J1200 Injection, diphenhydramine hcl, up to 50 mg
96415 Administration of chemotherapy into vein, each additional hour
82607 Cyanocobalamin (vitamin b-12) level
96360 Infusion into a vein for hydration, 31-60 minutes
83735 Magnesium level
J7030 Infusion, normal saline solution , 1000 cc
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
82306 Vitamin d-3 level
99221 Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
84443 Blood test, thyroid stimulating hormone (tsh)
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J3490 Unclassified drugs
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96411 Administration of additional new drug or substance into vein using push technique
96523 Irrigation of implanted venous access drug delivery device
82746 Folic acid level, serum
96361 Infusion into a vein for hydration, each additional hour
96521 Refilling and maintenance of portable pump
82232 Beta-2 microglobulin (protein) level
84155 Total protein level, blood
88184 Flow cytometry technique for dna or cell analysis, first marker
84439 Thyroxine (thyroid chemical), free
83010 Haptoglobin (serum protein) level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.